ArticleFrontiers in immunology2025

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer.

Kaixuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.